Skip to content

Welcome to Discover Pharma! Today is : November 8, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Discovery & Development

  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development

    CONNECTA starts Phase 2a trial of CTH120 for fragile X syndrome

    CONNECTA Therapeutics has started a Phase 2a clinical trial of [...]

    June 10, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing

    10x Genomics acquires Proteintech Genomics to expand single-cell proteomics capabilities

    10x Genomics has acquired Proteintech Genomics, a division within Proteintech [...]

    June 10, 2026
  • Biotech & Pharma Business,Drug Discovery & Development

    AmMax licenses Lonza ADC technology for AML programme

    AmMax Bio has licensed antibody-drug conjugate technology from Lonza to [...]

    June 10, 2026
  • Advanced Therapies,Drug Discovery & Development

    Cartesian licenses WestGene platform to advance in vivo CAR-T for autoimmune diseases

    Cartesian Therapeutics has signed a strategic licensing agreement with WestGene [...]

    June 9, 2026
  • Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Verdiva Bio unveils obesity drug data ahead of planned clinical entry

    Verdiva Bio has reported new preclinical data for two obesity [...]

    June 9, 2026
  • Digital & Data,Drug Discovery & Development

    Medable launches programme to support AI deployment in clinical development

    Medable has launched a new support programme aimed at helping [...]

    June 9, 2026
  • Digital & Data,Drug Discovery & Development,Manufacturing & Supply Chain

    Sapio Sciences and ZS partner on biopharma laboratory digitalisation

    Sapio Sciences has partnered with consulting and technology firm ZS [...]

    June 9, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Manufacturing & Supply Chain

    Lonza expands DNA-to-IND offering to accelerate biologics development timelines

    Lonza has expanded its integrated DNA-to-IND biologics development offering, introducing [...]

    June 8, 2026
  • Drug Discovery & Development,Opinion & Events,Pharmaceuticals and therapeutics

    Society for RNA Therapeutics expands leadership team

    The Society for RNA Therapeutics (SRT) has expanded its leadership [...]

    June 8, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Apoha raises $36M to expand molecular behaviour data platform

    London-based technology company Apoha has emerged from stealth with $36 [...]

    June 8, 2026
Previous151617Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Passive cough monitoring linked to worsening asthma symptoms
    Categories: Digital & Data, Drug Discovery & Development, Research & Development, Therapeutic Areas
  • NIH funds expanded access programme for Neurizon’s ALS therapy
    Categories: Advanced Therapies, Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Sapience Therapeutics gets FDA clearance for ST316 FAP study
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top